Alivira Spain continues its international expansion with the launch of its phenylpropanolamine-based product in several European countries. Following its successful establishment in Spain and Russia, the company will introduce Uristop®, under the Urixine® brand, to countries such as Portugal, Italy, Germany, Poland, Romania, Austria, Belgium, the Netherlands, and France, among others, totaling 15 countries. The product is expected to receive a similarly positive reception as in its home market.
With a strong presence in the Spanish market, Alivira aims to expand and strengthen its presence in Europe. “After several years of success in Spain, we have identified a growing demand in international markets and believe this is the right time to expand with Urixine,” said Matthieu Gonneaud, Europe Export Manager at Alivira Spain.
About Urixine®
The active ingredient in Urixine®, phenylpropanolamine, is the recommended and most widely used treatment in Spain for urinary incontinence in dogs due to urethral sphincter mechanism incompetence, a common issue in spayed female dogs, particularly those weighing over 20 kg.
With its syrup presentation and dosing syringe, Urixine® offers easy administration and an adaptable and precise dosage, making it ideal for the convenience of both veterinarians and pet owners.
